Researcher Professor Johann de Bono said: ‘There’s a lot of evidence that prostate cancer causes what we call immune tolerance — that the cancer suppresses the body from attacking it with its immune cells.
Scientists have discovered that a key protein may be the secret to treating prostate cancer patients with ‘miracle’ immunotherapy drugs.
Clinical trials have now begun – with the goal of unleashing cancer-killing white blood cells to attack the tumour.
Immunotherapies have had stunning results against some types of the disease.
Implantable electronics are among the most promising healthcare technologies, as they can help to remotely monitor specific biological processes associated with a patient’s health. While researchers have developed a variety of implantable devices over the past decade or so, existing technologies have several limitations that can prevent their widespread use in clinical settings.
The first factor preventing the large-scale implementation of existing implantable technologies is the structural mismatch between these devices and most organs/tissues in the body, which typically have complex 1D or 3D structures. Secondly, reliably fixing soft electronic devices on organs that are moving or pulsating has so far proved to be highly challenging.
Researchers at Daegu-Gyeongbuk Institute of Science & Technology (DGIST) in South Korea and ETH Zürich have recently developed a new fiber-based strain-sensing device that could overcome the limitations of existing implantable electronics. This sensor, presented in a paper published in Nature Electronics, comprises a capacitive fiber strain sensor with an inductive coil for wireless readout.
People who reach a very old age may have their genes to thank. Genetic variants that help to prevent DNA mutations and repair any that do occur have been found in supercentenarians and semi-supercentenarians – people who reach the ages of 110 and 105, respectively.
“DNA repair mechanisms are extremely efficient in these people,” says Claudio Franceschi at the University of Bologna in Italy. “It is one of the most important basic mechanisms for extending lifespan.”
Berlin, Gerrmany — Michael Greve, founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures, announced today that he will make available an additional €300 million to be invested in rejuvenation biotech.
The funds, to be deployed via Kizoo, will be used to create and support more startups in the rejuvenation space. They will also allow Kizoo to maintain a strong commitment to its key startups during follow-up rounds and to advance the therapies from clinical development to public availability.
With this €300 million commitment, Michael Greve and Kizoo double down on their mission to accelerate the advent of rejuvenation biotechnology by doing lighthouse investments in entirely new, repair-based approaches that treat the root causes of aging and thus overcome age-related diseases. Through the creation of successful companies, they seek to inspire scientists, investors, and the general public by demonstrating that human rejuvenation is not science fiction anymore and that the resulting therapies are affordable and uncomplicated.
The human cells grew inside all 132 of the embryos after just 24 hours. After ten days, 103 chimeric embryos remained. By day 19, however, only three chimeras were left alive – and they were then terminated.
“This knowledge will allow us to go back now and try to re-engineer these pathways that are successful for allowing appropriate development of human cells in these other animals,” Juan Carlos Izpisua Belmonte, genetics professor at the Salk Institute for Biological Sciences in La Jolla, California and co-author of the study, told NPR.
As India struggles to curb the spread of COVID-19 and step up vaccinations, experts have warned the country to prepare for future waves of the pandemic. It’s hoped that US support for a vaccine waiver will see results.
Many people with diabetes endure multiple, painful finger pricks each day to measure their blood glucose. Now, researchers reporting in ACS Sensors have developed a device that can measure glucose in sweat with the touch of a fingertip, and then a personalized algorithm provides an accurate estimate of blood glucose levels.
According to the American Diabetes Association, more than 34 million children and adults in the U.S. have diabetes. Although self-monitoring of blood glucose is a critical part of diabetes management, the pain and inconvenience caused by finger-stick blood sampling can keep people from testing as often as they should.
The researchers made a touch-based sweat glucose sensor with a polyvinyl alcohol hydrogel on top of an electrochemical sensor, which was screen-printed onto a flexible plastic strip. When a volunteer placed their fingertip on the sensor surface for 1 minute, the hydrogel absorbed tiny amounts of sweat. Inside the sensor, glucose in the sweat underwent an enzymatic reaction that resulted in a small electrical current that was detected by a hand-held device.
Deep-tech healthcare & energy investments for a sustainable future — dr. anil achyuta, investment director / founding member, TDK ventures.
Dr. Anil Achyuta is an Investment Director and a Founding Member at TDK Ventures, which is a deep-tech corporate venture fund of TDK Corporation, the Japanese multinational electronics company that manufactures electronic materials, electronic components, and recording and data-storage media.
Anil is passionate about energy and healthcare sectors as he believes these are the most impactful areas to building a sustainable future – a mission directly in line with TDK Ventures’ goal.
At TDK Ventures, Anil has reviewed over 1050 start-ups and invested in: 1) Autoflight — an electric vertical take-off and landing company, 2) Genetesis — a magnetic imaging-based cardiac diagnostics company, 3) Origin — 3D printing mass manufacturing company, 4) Exo — hand-held 3D ultrasound imaging company, 5) GenCell — ammonia-to-energy hydrogen fuel cell company, 6) Mojo Vision – augmented reality contact lens company, and 7) Battery Resourcers – a direct to cathode lithium ion battery recycling company.
From his seven investments, Anil has secured two exits. GenCell IPO’d on Tel Aviv’s Stock Exchange, and Origin was acquired by the #1 3D Printing company in the world, Stratasys, for $100M.
